Senti Biosciences (SNTI) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Senti Biosciences (SNTI) has outperformed Vistagen Therapeutics (VTGN) over the past year, losing 81.9% versus a loss of 93.9%. Over five years, VTGN leads with a -99.7% price change compared with -99.7% for SNTI. Vistagen Therapeutics is the larger company by market cap ($10.9 million vs $10.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNTI | VTGN |
|---|---|---|
| Share price | $0.3217 | $0.2462 |
| Market cap | $10.02M | $10.93M |
| 1-day change | -2.52% | -0.36% |
| YTD return | -69.07% | -62.70% |
| 1-year return | -81.93% | -93.88% |
| 5-year return | -99.68% | -99.66% |
| EPS (TTM) | $-1.72 | $-1.66 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.88 | $5.14 |
| 52-week low | $0.29 | $0.20 |
| Distance from 52-week high | -88.83% | -95.21% |
| Analyst consensus | none | none |
| Avg. price target upside | +4096.46% | +306.17% |
| Average volume | 573.78K | 12.38M |
| Shares outstanding | 31.15M | 44.38M |
| Employees | 39 | 41 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SNTI has outperformed VTGN by 11.9 percentage points over the past year.
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Healthcare · Biotechnology · 39 employees
About Vistagen Therapeutics
VTGN stock →Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Healthcare · Biotechnology · 41 employees
SNTI vs VTGN FAQ
Which is bigger, Senti Biosciences or Vistagen Therapeutics?
Vistagen Therapeutics (VTGN) is larger, with a market capitalization of $10.93M compared with $10.02M for Senti Biosciences (SNTI).
Which stock has performed better over the past year, SNTI or VTGN?
SNTI returned -81.93% over the past 12 months, compared with -93.88% for VTGN (price return, excluding dividends). Past performance does not predict future results.
Are Senti Biosciences and Vistagen Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.